Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren vs Amlodipine in Hypertensive Obese Patients
NCT00498433Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2007
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aliskiren in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoints: Aliskiren Concentrations From Interstitial Fluid (Microdialysis) at Day 42, Amlodipine Concentrations From Interstitial Fluid (Microdialysis) at Day 98 and 13 more. Started Jun 2007; status: terminated.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00498433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498433.